



(51) International Patent Classification:

C07D 471/14 (2006.01) A61P 35/00 (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2019/030633

(22) International Filing Date:

03 May 2019 (03.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/667,166 04 May 2018 (04.05.2018) US
62/815,539 08 March 2019 (08.03.2019) US

(71) Applicant: INCYTE CORPORATION [US/US]; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(72) Inventors: BURN, Timothy C.; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). LIU, Phillip C.; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). FRIETZE, William; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). JIA, Zhongjiang; 1801 Au-



gustine Cut-Off, Wilmington, Delaware 19803 (US). TAO, Ming; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). WANG, Dengjin; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). ZHOU, Jiacheng; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). LI, Qun; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(74) Agent: SEARS, Justin Edward et al.; Fish & Richardson P.C., P.O.Box 1022, Minneapolis, Minnesota 55440 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME

FIG. 1



(57) Abstract: The present disclosure relates to solid forms and polymorphs of compound (1): 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

26 December 2019 (26.12.2019)